Fangjian Zhou

机构：Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China · ORCID：0000-0001-5225-9012

发表论文 71 篇 · 总被引 623 次 · h-index 13

代表论文

• Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial (2023 · Annals of Oncology · 被引 82)
• A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma (2024 · European Journal of Cancer · 被引 11)
• First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial (2025 · The Lancet Oncology · 被引 10)
• Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors (2025 · Annals of Oncology · 被引 5)
• Regional lymph node mapping in patients with penile cancer undergoing radical inguinal lymph node dissection – a retrospective cohort study (2024 · International Journal of Surgery · 被引 5)
• Prognostic Value of Inflammation Biomarkers in Penile Squamous Cell Carcinoma Patients Without Distant Metastasis (2023 · Clinical Genitourinary Cancer · 被引 3)